298 research outputs found
A higher order panel method for linearized supersonic flow
The basic integral equations of linearized supersonic theory for an advanced supersonic panel method are derived. Methods using only linear varying source strength over each panel or only quadratic doublet strength over each panel gave good agreement with analytic solutions over cones and zero thickness cambered wings. For three dimensional bodies and wings of general shape, combined source and doublet panels with interior boundary conditions to eliminate the internal perturbations lead to a stable method providing good agreement experiment. A panel system with all edges contiguous resulted from dividing the basic four point non-planar panel into eight triangular subpanels, and the doublet strength was made continuous at all edges by a quadratic distribution over each subpanel. Superinclined panels were developed and tested on s simple nacelle and on an airplane model having engine inlets, with excellent results
A Three-Dimensional Solution of Flows over Wings with Leading-Edge Vortex Separation. Part 1: Engineering Document
A method of predicting forces, moments, and detailed surface pressures on thin, sharp-edged wings with leading-edge vortex separation in incompressible flow is presented. The method employs an inviscid flow model in which the wing and the rolled-up vortex sheets are represented by piecewise, continuous quadratic doublet sheet distributions. The Kutta condition is imposed on all wing edges. Computed results are compared with experimental data and with the predictions of the leading-edge suction analogy for a selected number of wing planforms over a wide range of angle of attack. These comparisons show the method to be very promising, capable of producing not only force predictions, but also accurate predictions of detailed surface pressure distributions, loads, and moments
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Effect of nocturnal ventilation on the occurrence of Botrytis cinerea in Mediterranean unheated tomato greenhouses
Botrytis cinerea is the causal agent of grey mould disease which is one of the most important diseases affecting tomato crops in unheated greenhouses. Nocturnal ventilation is a technique that can be used to reduce relative humidity inside unheated greenhouses. The main objectives of this research were to investigate the effect of ventilation management on the environmental conditions and on the disease severity, to develop and validate a model which could predict disease severity and to present a warning system.
Experiments were conducted in two plastic greenhouses. Two natural ventilation treatments were randomly assigned to the greenhouses. One was nocturnal ventilation (NV), with the vents open during the day and night, while the other was classical ventilation (CV), in which the vents were open during the day and closed during the night.
A tomato crop was grown directly in the soil between the end of February and the end of July during two crop seasons. Climatic data were measured with three meteorological stations, averaged and recorded on an hourly basis. The number of diseased leaflets were counted and removed from the greenhouse.
In the NV greenhouse a significant reduction of air humidity and disease appearance was observed. A warning system was developed and can be a useful tool for helping to decide on appropriate actions and the correct timing to avoid conditions that favour disease development. For a more practical application, disease risk levels were defined as a function of the duration of periods with RH > 90%
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Introduction: This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA) who had a prior inadequate response or intolerance to ≥ 1 non-biologic or biologic disease-modifying antirheumatic drug. Methods: Safety data were pooled and analyzed from two randomized, placebo-controlled phase 3 trials. Both trials evaluated upadacitinib 15 mg and 30 mg once daily, and one trial also evaluated adalimumab 40 mg every other week. Treatment-emergent adverse events (TEAEs) and laboratory data were summarized for four groups: pooled placebo, pooled upadacitinib 15 mg, pooled upadacitinib 30 mg, and adalimumab. TEAEs were reported as exposure-adjusted event rates (events per 100 patient-years [E/100 PY]) up to a data cut-off of June 29, 2020. Results: A total of 2257 patients received ≥ 1 dose of upadacitinib 15 mg (N = 907) or 30 mg (N = 921) for 2504.6 PY of exposure or adalimumab (N = 429) for 549.7 PY of exposure. Upper respiratory tract infection, nasopharyngitis, and increased creatine phosphokinase (CPK) were the most common TEAEs with upadacitinib. Rates of malignancies, adjudicated major adverse cardiovascular events (MACEs) and venous thromboembolic events (VTEs), and deaths were similar across treatment groups. Rates of herpes zoster (HZ) and opportunistic infections (OI; excluding tuberculosis, HZ, and oral candidiasis) were higher with upadacitinib versus adalimumab. Serious infection, anemia, and CPK elevations were most frequent with upadacitinib 30 mg. Potentially clinically significant laboratory abnormalities were uncommon. Conclusions: Upadacitinib 15 mg and adalimumab had similar safety profiles with the exception of HZ and OIs, consistent with what was observed in rheumatoid arthritis. Rates of malignancies, MACEs, VTEs, and deaths were comparable among patients receiving upadacitinib and adalimumab. No new safety risks emerged with longer-term exposure to upadacitinib. Trial Registration Numbers: SELECT-PsA 1: NCT03104400; SELECT-PsA 2: NCT03104374
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
OBJECTIVES
To correlate immune responses following a two-dose regimen of mRNA anti-SARS-CoV-2 vaccines in patients with rheumatoid arthritis (RA) to the development of a potent neutralising antiviral activity.
METHODS
The RECOVER study was a prospective, monocentric study including patients with RA and healthy controls (HCs). Assessments were performed before, and 3, 6, 12 and 24 weeks, after the first vaccine dose, respectively, and included IgG, IgA and IgM responses (against receptor binding domain, S1, S2, N), IFN-γ ELISpots as well as neutralisation assays.
RESULTS
In patients with RA, IgG responses developed slower with lower peak titres compared with HC. Potent neutralising activity assessed by a SARS-CoV-2 pseudovirus neutralisation assay after 12 weeks was observed in all 21 HCs, and in 60.3% of 73 patients with RA. A significant correlation between peak anti-S IgG levels 2 weeks after the second vaccine dose and potent neutralising activity against SARS-CoV-2 was observed at weeks 12 and 24. The analysis of IgG, IgA and IgM isotype responses to different viral proteins demonstrated a delay in IgG but not in IgA and IgM responses. T cell responses were comparable in HC and patients with RA but declined earlier in patients with RA.
CONCLUSION
In patients with RA, vaccine-induced IgG antibody levels were diminished, while IgA and IgM responses persisted, indicating a delayed isotype switch. Anti-S IgG levels 2 weeks after the second vaccine dose correlate with the development of a potent neutralising activity after 12 and 24 weeks and may allow to identify patients who might benefit from additional vaccine doses or prophylactic regimen
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis
Objective. To assess the efficacy and safety profiles of two different rituximab retreatment regimens in patients with RA
- …